|
1
|
Cheng JS, Chou CT, Liu YY, Sun WC, Shieh
P, Kuo DH, Kuo CC, Jan CR and Liang WZ: The effect of oleuropein
from olive leaf (Olea europaea) extract on Ca2+
homeostasis, cytotoxicity, cell cycle distribution and ROS
signaling in HepG2 human hepatoma cells. Food Chem Toxicol.
91:151–166. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feng M, Gao W, Wang R, Chen W, Man YG,
Figg WD, Wang XW, Dimitrov DS and Ho M: Therapeutically targeting
glypican-3 via a conformation-specific single-domain antibody in
hepatocellular carcinoma. Proc Natl Acad Sci USA. 110:E1083–E1091.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wilson TR, Fridlyand J, Yan Y, Penuel E,
Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al:
Widespread potential for growth-factor-driven resistance to
anticancer kinase inhibitors. Nature. 487:505–509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Q, Ma S, Liu B, Liu J, Zhu R and Li
M: Chrysin induces cell apoptosis via activation of the
p53/Bcl-2/caspase-9 pathway in hepatocellular carcinoma cells. Exp
Ther Med. 12:469–474. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Au JS and Frenette CT: Management of
hepatocellular carcinoma: Current status and future directions. Gut
Liver. 9:437–448. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu G, Fan X, Tang M, Chen R, Wang H, Jia
R, Zhou X, Jing W, Wang H, Yang Y, et al: Osteopontin induces
autophagy to promote chemo-resistance in human hepatocellular
carcinoma cells. Cancer Lett. 383:171–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luo HL, Chen J, Luo T, Wu FX, Liu JJ, Wang
HF, Chen M, Li LQ and Li H: Downregulation of macrophage-derived
T-UCR uc.306 associates with poor prognosis in hepatocellular
carcinoma. Cell Physiol Biochem. 42:1526–1539. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bruix J, Takayama T, Mazzaferro V, Chau
GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, et al: Adjuvant
sorafenib for hepatocellular carcinoma after resection or ablation
(STORM): A phase 3, randomised, double-blind, placebo-controlled
trial. Lancet Oncol. 16:1344–1354. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Horgan AM, Dawson LA, Swaminath A and Knox
JJ: Sorafenib and radiation therapy for the treatment of advanced
hepatocellular carcinoma. J Gastrointest Cancer. 43:344–348. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tabernero J, Garcia-Carbonero R, Cassidy
J, Sobrero A, Van Cutsem E, Köhne CH, Tejpar S, Gladkov O,
Davidenko I, Salazar R, et al: Sorafenib in combination with
oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as
first-line treatment of metastatic colorectal cancer: The RESPECT
trial. Clin Cancer Res. 19:2541–2550. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar
|
|
13
|
Wang L, Chang J, Varghese D, Dellinger M,
Kumar S, Best AM, Ruiz J, Bruick R, Peña-Llopis S, Xu J, et al: A
small molecule modulates Jumonji histone demethylase activity and
selectively inhibits cancer growth. Nat Commun. 4:20352013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Olivier M, Hollstein M and Hainaut P: TP53
mutations in human cancers: Origins, consequences, and clinical
use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Osborne C, Wilson P and Tripathy D:
Oncogenes and tumor suppressor genes in breast cancer: Potential
diagnostic and therapeutic applications. Oncologist. 9:361–377.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Freed-Pastor WA, Mizuno H, Zhao X,
Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li
W, Polotskaia A, et al: Mutant p53 disrupts mammary tissue
architecture via the mevalonate pathway. Cell. 148:244–258. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bailey SM, Meyne J, Chen DJ, Kurimasa A,
Li GC, Lehnert BE and Goodwin EH: DNA double-strand break repair
proteins are required to cap the ends of mammalian chromosomes.
Proc Natl Acad Sci USA. 96:14899–14904. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vazquez A, Bond EE, Levine AJ and Bond GL:
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat
Rev Drug Discov. 7:979–987. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Degenhardt K, Chen G, Lindsten T and White
E: BAX and BAK mediate p53-independent suppression of
tumorigenesis. Cancer Cell. 2:193–203. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Henry H, Thomas A, Shen Y and White E:
Regulation of the mitochondrial checkpoint in p53-mediated
apoptosis confers resistance to cell death. Oncogene. 21:748–760.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mauer K, O'Kelley R, Poddar N, Flanagan S
and Gadani S: Erratum to: New treatment modalities for
hepatocellular cancer. Curr Gastroenterol Rep. 17:492015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Deng T, Zeng L and Chen W:
Efficacy and safety of radiofrequency ablation and transcatheter
arterial chemoembolization for treatment of hepatocellular
carcinoma: A meta-analysis. Hepatol Res. 46:58–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ding G, Peng Z, Shang J, Kang Y, Ning H
and Mao C: LincRNA-p21 inhibits invasion and metastasis of
hepatocellular carcinoma through miR-9/E-cadherin cascade signaling
pathway molecular mechanism. Onco Targets Ther. 10:3241–3247. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alenzi FQ, Alenazi BQ, Al-Anazy FH,
Mubaraki AM, Salem ML, Al-Jabri AA, Lotfy M, Bamaga MS, Alrabia MW
and Wyse RK: The role of caspase activation and mitochondrial
depolarisation in cultured human apoptotic eosinophils. Saudi J
Biol Sci. 17:29–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu S, Liu B, Zhang Q, Liu J, Zhou W, Wang
C, Li M, Bao S and Zhu R: Dihydromyricetin reduced Bcl-2 expression
via p53 in human hepatoma HepG2 cells. PLoS One. 8:e768862013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Powell CB, Fung P, Jackson J, Dal l'Era J,
Lewkowicz D, Cohen I and Smith-McCune K: Aqueous extract of herba
Scutellaria barbatae, a chinese herb used for ovarian cancer,
induces apoptosis of ovarian cancer cell lines. Gynecol Oncol.
91:332–340. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yuan CH, Filippova M and Duerksen-Hughes
P: Modulation of apoptotic pathways by human papillomaviruses
(HPV): Mechanisms and implications for therapy. Viruses.
4:3831–3850. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
McIlwain DR, Berger T and Mak TW: Caspase
functions in cell death and disease. Cold Spring Harb Perspect
Biol. 5:a0086562013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Poku RA, Salako OO, Amissah F, Nkembo AT,
Ntantie E and Lamango NS: Polyisoprenylated cysteinyl amide
inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit
migration and invasion of metastatic prostate cancer cells. Am J
Cancer Res. 7:1515–1527. 2017.PubMed/NCBI
|
|
30
|
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT,
Liu B and Bao JK: Programmed cell death pathways in cancer: A
review of apoptosis, autophagy and programmed necrosis. Cell
Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Booth L, Cruickshanks N, Ridder T, Dai Y,
Grant S and Dent P: PARP and CHK inhibitors interact to cause DNA
damage and cell death in mammary carcinoma cells. Cancer Biol Ther.
14:458–465. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ciccarone F, Klinger FG, Catizone A,
Calabrese R, Zampieri M, Bacalini MG, De Felici M and Caiafa P:
Poly(ADP-ribosyl)ation acts in the DNA demethylation of mouse
primordial germ cells also with DNA damage-independent roles. PLoS
One. 7:e469272012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Q, Liu J, Liu B, Xia J, Chen N, Chen
X, Cao Y, Zhang C, Lu C, Li M, et al: Dihydromyricetin promotes
hepatocellular carcinoma regression via a p53 activation-dependent
mechanism. Sci Rep. 4:46282014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reed JC: Bcl-2 family proteins: Regulators
of apoptosis and chemoresistance in hematologic malignancies. Semin
Hematol. 34 4 Suppl 5:S9–S19. 1997.
|
|
35
|
Pettersson F, Dalgleish AG, Bissonnette RP
and Colston KW: Retinoids cause apoptosis in pancreatic cancer
cells via activation of RAR-gamma and altered expression of
Bcl-2/Bax. Br J Cancer. 87:555–561. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Peña-Blanco A and García-Sáez AJ: Bax, Bak
and beyond-mitochondrial performance in apoptosis. FEBS J.
285:416–431. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carr MI and Jones SN: Regulation of the
Mdm2-p53 signaling axis in the DNA damage response and
tumorigenesis. Transl Cancer Res. 5:707–724. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Haupt Y, Maya R, Kazaz A and Oren M: Mdm2
promotes the rapid degradation of p53. Nature. 387:296–299. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Minsky N and Oren M: The RING domain of
Mdm2 mediates histone ubiquitylation and transcriptional
repression. Mol Cell. 16:631–639. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kubbutat MH, Jones SN and Vousden KH:
Regulation of p53 stability by Mdm2. Nature. 387:299–303. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mu R, Lu N, Wang J, Yin Y, Ding Y, Zhang
X, Gui H, Sun Q, Duan H, Zhang L, et al: An oxidative analogue of
gambogic acid-induced apoptosis of human hepatocellular carcinoma
cell line HepG2 is involved in its anticancer activity in vitro.
Eur J Cancer Prev. 19:61–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Papazoglu C and Mills AA: p53: At the
crossroad between cancer and ageing. J Pathol. 211:124–133. 2007.
View Article : Google Scholar : PubMed/NCBI
|
